27 terminated. 27 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Terminated 27 |
| Phase 2 | 1 | Terminated 1 |
Follow Hepatitis, Chronic: new trials by email Literature Review of Hepatitis, Chronic trials Research Report on Hepatitis, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Primary Prevention Hepatocellular Carcinoma by Metformin Metformin, placebo tablet - Hepatocellular Carcinoma, Hepatitis C, Chronic | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 11 | 2015-06-01 | 2017-01-11 |
| Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection Telbivudine, Placebo - Chronic Hepatitis B | Phase 3 | Terminated | Novartis Pharmaceuticals | 53 | 2014-10-31 | 2019-09-10 |
| A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450) PEG-Intron™, PEGASYS™ - Hepatitis B, Chronic | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 402 | 2012-11-26 | 2018-08-27 |
| 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study Previous treatment in DEB025 study - Hepatitis C, Chronic | Phase 3 | Terminated | Novartis Pharmaceuticals | 105 | 2012-09-06 | 2018-01-12 |
| Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Tenofovir, Placebo - Chronic Hepatitis B, Hepatocellular Carcinoma | Phase 3 | Terminated | Taichung Veterans General Hospital | 320 | 2012-09-01 | 2014-09-04 |
| Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα Entecavir, Placebo - Chronic Hepatitis B, Rheumatoid Arthritis | Phase 3 | Terminated | Seoul National University Hospital | 43 | 2012-09-01 | 2017-03-06 |
| Long Term Vitamin D Therapy in HCV Treated Patients Vitamin D - Chronic Hepatitis C | Phase 3 | Terminated | Dr. Nadia AbdelAaty AbdelKader | 100 | 2012-04-01 | 2013-11-28 |
| Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1 Alisporivir, Boceprevir, Peginterferon alfa-2a - Hepatitis C | Phase 3 | Terminated | Debiopharm International SA | 8 | 2011-12-01 | 2017-01-16 |
| Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin - Hepatitis C, Chronic | Phase 3 | Terminated | Vertex Pharmaceuticals Incorporated | 239 | 2011-11-01 | 2015-06-10 |
| EXtended Therapy in Hepatitis C Genotype 3 Infected Patients Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol) - Chronic Hepatitis C | Phase 3 | Terminated | University Health Network, Toronto | 2 | 2010-02-01 | 2011-09-29 |
| Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance Pioglitazone, Placebo - Chronic Hepatitis C, Insulin Resistance | Phase 3 | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | 40 | 2009-12-03 | 2017-01-24 |
| A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection Entecavir + Tenofovir, Adefovir + continuing Lamivudine - Chronic Hepatitis B | Phase 3 | Terminated | Bristol-Myers Squibb | 4 | 2008-08-01 | 2010-11-23 |
| High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4 ribavirin - Chronic Hepatitis C | Phase 3 | Terminated | Foundation for Liver Research | 110 | 2008-04-01 | 2014-07-14 |
| Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus Clevudine, Adefovir - Chronic Hepatitis, Hepatitis B | Phase 3 | Terminated | Pharmasset | 2007-08-01 | 2009-04-27 | |
| Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus Clevudine, Adefovir - Chronic Hepatitis, Hepatitis B | Phase 3 | Terminated | Pharmasset | 2007-08-01 | 2009-04-27 | |
| Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) Boceprevir, Narlaprevir, Peginterferon alfa-2b - Hepatitis C, Chronic, Hepacivirus | Phase 2 / Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1954 | 2007-02-20 | 2018-09-11 |
| Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED) Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV) - Hepatitis C, Chronic | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 56 | 2006-12-01 | 2017-04-07 |
| Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Telbivudine (LdT), peginterferon alpha-2a - Hepatitis B | Phase 3 | Terminated | Novartis | 159 | 2006-12-01 | 2011-07-13 |
| Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) Peginterferon alfa-2b (PegIFN-2b), Comparator: Stronger neo minophagen C (SNMC) - Hepatitis C, Chronic | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 261 | 2006-12-01 | 2017-04-06 |
| Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation ciclosporin - Chronic Hepatitis C, Evidence of Liver Transplantation | Phase 3 | Terminated | Rennes University Hospital | 11 | 2006-06-01 | 2012-03-02 |
Showing 20 of 27. Sign in to see all of them.
Hepatitis C, Chronic (18) · Hepatitis B, Chronic (7) · Hepatitis C (7) · Hepatitis B (4) · Carcinoma, Hepatocellular (2) · HIV Infections (2) · Liver Cirrhosis (2) · Acquired Immunodeficiency Syndrome (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Bronchiolitis Obliterans Syndrome (1) · Death (1) · Fatty Liver (1)
Blood-Borne Infections (27) · Chronic Disease (27) · Communicable Diseases (27) · Digestive System Diseases (27) · Disease Attributes (27) · Hepatitis (27) · Hepatitis, Viral, Human (27) · Infections (27) · Liver Diseases (27) · Pathologic Processes (27) · Pathological Conditions, Signs and Symptoms (27) · Virus Diseases (27) · RNA Virus Infections (19) · Flaviviridae Infections (18)
Ribavirin (12) · peginterferon alfa-2b (8) · peginterferon alfa-2a (7) · Tenofovir (3) · adefovir (3) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (2) · Telbivudine (2) · clevudine (2) · entecavir (2) · Amantadine (1) · Blood Specimen Collection (1) · Capsules (1) · Cyclosporine (1) · Metformin (1) · Pioglitazone (1)
Merck Sharp & Dohme LLC (6) · French National Agency for Research on AIDS and Viral Hepatitis (3) · Novartis Pharmaceuticals (2) · Pharmasset (2) · University Health Network, Toronto (2) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · Debiopharm International SA (1) · Dr. Nadia AbdelAaty AbdelKader (1) · Foundation for Liver Research (1) · Hoffmann-La Roche (1) · Novartis (1) · Rennes University Hospital (1) · Seoul National University Hospital (1) · Taichung Veterans General Hospital (1)
United States (7) · Canada (6) · France (5) · Germany (4) · Taiwan (4) · Australia (3) · Belgium (3) · Greece (3) · Poland (3) · Puerto Rico (3) · South Korea (3) · Spain (3) · Thailand (3) · Argentina (2) · China (2)
Amany Y Elkazaz (1) · Anita Rachlis, MD (1) · Benoit Trottier, MD (1) · Chris Fraser, MD (1) · Christian Trepo, MD (1) · Chun-Ying Wu, MD, PhD, MPH (1) · Curtis Cooper, MD (1) · Dina Sabry (1) · Dominique Roulot, MD (1) · E. Jenny Heathcote, MB,BS,MD,FRCP,FRCP(C) (1) · Eric Bellissant, MD, PhD (1) · Helene Fontaine, MD (1)
2005 (1), 2008 (1)